Clinical Outcomes of Non-Small Cell Lung Cancer (NSCLC) Patients with ALK Co-Mutations (EGFR or KRAS) Receiving Tyrosine Kinase Inhibitors (TKI)

被引：0

作者：

Schmid, Sabine ^{[1
]}

Gautschi, Oliver ^{[2
]}

Rothschild, Sacha ^{[3
]}

Mauti, Laetitia ^{[4
]}

Mark, Michael ^{[5
]}

Froesch, Patrizia ^{[6
]}

Fruh, Martin ^{[1
]}

机构：

[1] Kantonsspital St Gallen, St Gallen, Switzerland

[2] Lucerne Cantonal Hosp, Med Oncol, Luzern, Switzerland

[3] Univ Hosp Basel, Med Oncol, Basel, Switzerland

[4] Kantonsspital Winterthur, Winterthur, Switzerland

[5] Kantonsspital Graubunden, Chur, Switzerland

[6] Eoc, Bellinzona, Switzerland

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期

关键词：

KRAS; EGFR; Co-Mutations; ALK;

D O I：

10.1016/j.jtho.2016.11.2070

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PUB100

引用

页码：S1505 / S1505

页数：1

共 50 条

[1] Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)
Schmid, Sabine
Gautschi, Oliver
Rothschild, Sacha
Mark, Michael
Froesch, Patrizia
Klingbiel, Dirk
Reichegger, Hermann
Jochum, Wolfram
Diebold, Joachim
Fruh, Martin
[J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (04) : 681 - 688
[2] Acquired EGFR Resistant Mutations and Co-mutations in Tumors Of Non-small Cell Lung Cancer Patients Treated With Tyrosine Kinase Inhibitors (TKI)
Raez, Luis E.
Baca, Yasmine
Carracedo, Carlos
Vanderwalde, Ari
Nabhan, Chadi
Nagasaka, Misako
Nieva, Jorge
Mandani, Hirva
Borghaei, Hossein
Socinski, Mark
Khan, Hina
Wozniak, Antoinette
Lopes, Gilberto
Liu, Stephen
[J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : S3 - S3
[3] Multiplicity of EGFR and KRAS Mutations in Non-small Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors
Benesova, Lucie
Minarik, Marek
Jancarikova, Dana
Belsanova, Barbora
Pesek, Milos
[J]. ANTICANCER RESEARCH, 2010, 30 (05) : 1667 - 1671
[4] Developing of EGFR resistant mutations to Tyrosine Kinase Inhibitors (TKI) in Non-Small Cell Lung Cancer (NSCLC)
Raez, L. E.
Baca, Y.
Nagasaka, M.
Nieva, J.
Mandani, H.
Wanderwalde, A.
Borghaei, H.
Naban, C.
Langer, C.
Socinsky, M. A.
Lopes, G.
Khan, H.
Wozniak, A.
Carracedo, C.
Liu, S.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S597 - S597
[5] Clinical characteristics, co-mutations and outcomes of advanced non-small cell lung cancer (NSCLC) patients with KRAS mutations.
Muthiah, Arun
Chudasama, Rani
Olszewski, Adam J.
Saiganesh, Harish
Kurt, Habibe
Mingrino, Jennifer
Garcia-Moliner, Maria
Azzoli, Christopher G.
Khurshid, Humera
Birnbaum, Ariel E.
Khan, Hina
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[6] TUMOR BURDEN AND TYROSINE KINASE INHIBITORS (TKI) BENEFIT IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH EGFR SENSITIZING MUTATIONS (EGFRM) AND ALK REARRANGEMENT (ALK plus )
Leduc, C.
Moussa, N.
Faivre, L.
Biondani, P.
Pignon, J.
Caramella, C.
Besse, B.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (04) : S37 - S37
[7] Treatment outcomes with tyrosine kinase inhibitors in patients with uncommon EGFR mutations in non-small cell lung cancer
Hunter, S.
Nickless, G.
Ghosh, S.
Lal, R.
Merrick, S. A.
Montes, A.
Smith, D.
Spicer, J.
Karapanagiotou, E.
[J]. LUNG CANCER, 2017, 103 : S34 - S35
[8] Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib
Yiming Zhao
Shuyuan Wang
Bo Zhang
Rong Qiao
Jianlin Xu
Lele Zhang
Yanwei Zhang
Baohui Han
[J]. Targeted Oncology, 2019, 14 : 169 - 178
[9] Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib
Zhao, Yiming
Wang, Shuyuan
Zhang, Bo
Qiao, Rong
Xu, Jianlin
Zhang, Lele
Zhang, Yanwei
Han, Baohui
[J]. TARGETED ONCOLOGY, 2019, 14 (02) : 169 - 178
[10] Co-mutations in EGFR driven non-small cell lung cancer
Rosell, Rafael
Karachaliou, Niki
[J]. EBIOMEDICINE, 2019, 42 : 18 - 19

← 1 2 3 4 5 →